Physician profile
James D'Antonio
NPI 1205055407
$17,237.65
in general payments reported to CMS, 2019-2025
26 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $74.12 · 2021: $186 · 2022: $1,934 · 2023: $68.33 · 2024: $2,702 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,774 · Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,774.06 |
| Food and Beverage | $1,469.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $11,796.52 | 2019-2025 | Starclose Se, Amplatzer Amulet |
| Cordis US Corp. | $2,130.26 | 2024 | Precise Pro Rx, Angioguard |
| Medtronic, INC. | $1,481.47 | 2022-2024 | Venaseal |
| Terumo Medical Corporation | $344.43 | 2022 | |
| Heartflow, INC. | $174.13 | 2025 | |
| Novartis Pharmaceuticals Corporation | $155.78 | 2019-2025 | |
| Shockwave Medical, INC | $155.43 | 2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Edwards Lifesciences Corporation | $135.66 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.96 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $121.25 | 2022-2024 | Xarelto |
| Inari Medical, INC. | $90.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $89.30 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $83.07 | 2022-2025 | Impella |
| Amgen INC. | $59.14 | 2019-2025 | |
| Novo Nordisk INC | $34.68 | 2024 | Ozempic, Rybelsus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $33.74 | 2021-2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Astrazeneca Pharmaceuticals LP | $29.61 | 2022 | |
| Alnylam Pharmaceuticals INC. | $29.46 | 2025 | Onpattro |
| Cardiovascular Systems INC. | $29.22 | 2019 | |
| Medtronic Vascular, INC. | $27.30 | 2019 | |
| Stryker Corporation | $26.19 | 2025 | Flowtriever |
| Bayer Healthcare Pharmaceuticals INC. | $19.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.39 | 2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $17.97 | 2019 | |
| Surmodics, INC. | $13.25 | 2025 | Pounce Venous Thrombectomy System, Sublime Microcatheter, 018, 200cm, Straight, Pounce Thrombectomy |
| Kowa Pharmaceuticals America, INC. | $13.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James D'Antonio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.